RTW Biotech Opportunities Ltd Transaction in Own Shares (1427Z)
January 10 2024 - 2:00AM
UK Regulatory
TIDMRTW
RNS Number : 1427Z
RTW Biotech Opportunities Ltd
10 January 2024
LEI: 549300Q7EXQQH6KF7Z84
10 January 2024
RTW Biotech Opportunities Ltd
(the "Company")
Transaction in Own Shares
The Company announces that on 9 January 2024 it bought back
250,000 of its own shares, to be held as treasury shares, at an
average price of $1.38 per share.
Further details are set out below:
Number of shares held as treasury shares following this
purchase: 2,003,791
Total shares in issue excluding treasury shares following this
purchase: 210,385,347
The Company has bought back these shares under the authority
granted by shareholders at its Annual General Meeting in June 2023,
which permits the Company to repurchase a maximum of 14.99% of its
ordinary shares. The actual number of shares repurchased by the
Company will depend on market conditions. This authority lasts
until the next shareholder authority granted (expected to be at the
Annual General Meeting in 2024), or until expressly revoked by
shareholders.
The above figure of 210,385,347 may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, the Company under the FCA's Disclosure and
Transparency Rules.
No maximum consideration payable has been determined by the
Company, but the Company is unable to pay a price for any shares
pursuant to the buyback which would equate to a premium to the net
asset value. It is the Company's current intention to hold any
shares bought back in treasury.
The Company has instructed Numis Securities Limited as its
broker in respect of its buyback transactions. This arrangement is
in accordance with the UKLA Listing Rules and the Company's general
authority to repurchase shares.
For Further Information:
RTW Investments, LP +44 (0)20 7959 6361
Woody Stileman, Managing Director
Krisha McCune, Director, Client Service
About RTW Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an
investment fund focused on identifying transformative assets with
high growth potential across the biopharmaceutical and medical
technology sectors. Driven by a long-term approach to support
innovative businesses, RTW Biotech Opportunities Ltd invests in
companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech
Opportunities Ltd is managed by RTW Investments, LP, a leading
healthcare-focused entrepreneurial investment firm with deep
scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
POSUKONRSVUARAR
(END) Dow Jones Newswires
January 10, 2024 02:00 ET (07:00 GMT)
Rtw Biotech Opportunities (LSE:RTWG)
Historical Stock Chart
From Oct 2024 to Nov 2024
Rtw Biotech Opportunities (LSE:RTWG)
Historical Stock Chart
From Nov 2023 to Nov 2024
